Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 200 of 403

1.

Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.

Sellebjerg F, Royen L, Soelberg Sørensen P, Oturai AB, Jensen PEH.

Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308. [Epub ahead of print]

PMID:
30113249
2.

Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.

Petersen ER, Søndergaard HB, Laursen JH, Olsson AG, Börnsen L, Soelberg Sørensen P, Sellebjerg F, Bang Oturai A.

Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753. [Epub ahead of print]

PMID:
30070595
3.

Early versus later treatment start in multiple sclerosis: a register-based cohort study.

Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS; Danish Multiple Sclerosis Group.

Eur J Neurol. 2018 May 30. doi: 10.1111/ene.13692. [Epub ahead of print]

PMID:
29847005
4.

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.

Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875. [Epub ahead of print]

PMID:
29716436
5.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25.

6.

Progressive multiple sclerosis, cognitive function, and quality of life.

Højsgaard Chow H, Schreiber K, Magyari M, Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Soelberg Sørensen P, Sellebjerg F.

Brain Behav. 2018 Jan 5;8(2):e00875. doi: 10.1002/brb3.875. eCollection 2018 Feb.

7.

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.

Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, Dangond F, Giovannoni G.

Ther Adv Neurol Disord. 2018 Jan 23;11:1756285617753365. doi: 10.1177/1756285617753365. eCollection 2018.

8.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
9.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
10.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
11.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
12.

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler Relat Disord. 2018 Feb;20:73-77. doi: 10.1016/j.msard.2017.12.010. Epub 2017 Dec 18.

PMID:
29324249
13.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
14.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

15.

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.

Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M.

Neurology. 2017 Oct 17;89(16):1668-1675. doi: 10.1212/WNL.0000000000004508. Epub 2017 Sep 20.

PMID:
28931645
16.

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.

Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603. [Epub ahead of print]

PMID:
28870107
17.

Defining active progressive multiple sclerosis.

Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermind LE, von Essen M, Ratzer RL, Soelberg Sørensen P, Romme Christensen J.

Mult Scler. 2017 Nov;23(13):1727-1735. doi: 10.1177/1352458517726592. Epub 2017 Aug 23.

PMID:
28831853
18.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group.

Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]

19.

Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships.

Thormann A, Sørensen PS, Koch-Henriksen N, Thygesen LC, Laursen B, Magyari M.

Eur J Neurol. 2017 Jun;24(6):825-834. doi: 10.1111/ene.13297.

PMID:
28544411
20.

Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.

Blinkenberg M, Soelberg Sørensen P.

CNS Drugs. 2017 May;31(5):357-371. doi: 10.1007/s40263-017-0414-3. Review.

PMID:
28285378
21.

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V.

Int J MS Care. 2017 Jan-Feb;19(1):16-24. doi: 10.7224/1537-2073.2015-024.

22.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

23.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
24.

Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.

Lundell H, Svolgaard O, Dogonowski AM, Romme Christensen J, Selleberg F, Soelberg Sørensen P, Blinkenberg M, Siebner HR, Garde E.

Acta Neurol Scand. 2017 Oct;136(4):330-337. doi: 10.1111/ane.12729. Epub 2017 Jan 10.

PMID:
28070886
25.

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L.

Mult Scler Relat Disord. 2016 Nov;10:66-72. doi: 10.1016/j.msard.2016.09.001. Epub 2016 Sep 6.

PMID:
27919501
26.

Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort.

Thormann A, Koch-Henriksen N, Laursen B, Sørensen PS, Magyari M.

Mult Scler Relat Disord. 2016 Nov;10:181-186. doi: 10.1016/j.msard.2016.10.008. Epub 2016 Oct 29.

PMID:
27919487
27.

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Nov;10:169-173. doi: 10.1016/j.msard.2016.10.005. Epub 2016 Oct 26.

PMID:
27919484
28.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
29.

Safety concerns and risk management of multiple sclerosis therapies.

Soelberg Sorensen P.

Acta Neurol Scand. 2017 Sep;136(3):168-186. doi: 10.1111/ane.12712. Epub 2016 Nov 27. Review.

PMID:
27891572
30.

Evolving concepts in the treatment of relapsing multiple sclerosis.

Comi G, Radaelli M, Soelberg Sørensen P.

Lancet. 2017 Apr 1;389(10076):1347-1356. doi: 10.1016/S0140-6736(16)32388-1. Epub 2016 Nov 24. Review.

PMID:
27889192
31.

The Danish Multiple Sclerosis Treatment Register.

Magyari M, Koch-Henriksen N, Sørensen PS.

Clin Epidemiol. 2016 Oct 25;8:549-552. eCollection 2016. Review.

32.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, Hincelin-Mery A, Sikkema D, Pallardy M, Kieseier B, Hemmer B, Hartung HP, Soelberg Sorensen P, Deisenhammer F, Dönnes P, Davidson J, Fogdell-Hahn A, Broët P; ABIRISK Consortium.

PLoS One. 2016 Nov 2;11(11):e0162752. doi: 10.1371/journal.pone.0162752. eCollection 2016.

33.

NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: cotsapas@broadinstitute.org; International Multiple Sclerosis Genetics Consortium.

Neuron. 2016 Oct 19;92(2):333-335. doi: 10.1016/j.neuron.2016.09.052.

34.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

35.

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

J Neurol. 2016 Dec;263(12):2484-2493. Epub 2016 Oct 3.

PMID:
27699465
36.

Employment, disability pension and income for children with parental multiple sclerosis.

Moberg JY, Laursen B, Koch-Henriksen N, Thygesen LC, Brødsgaard A, Soelberg Sørensen P, Magyari M.

Mult Scler. 2017 Jul;23(8):1148-1156. doi: 10.1177/1352458516672016. Epub 2016 Sep 28.

PMID:
27682230
37.

Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study.

Moberg JY, Magyari M, Koch-Henriksen N, Thygesen LC, Laursen B, Soelberg Sørensen P.

J Neurol. 2016 Nov;263(11):2229-2237. Epub 2016 Aug 19.

PMID:
27541043
38.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

39.

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, Börnsen L, Romme Christensen J, Ratzer R, Siebner HR, Laursen B, Soelberg Sorensen P.

Mult Scler. 2017 Apr;23(5):675-685. doi: 10.1177/1352458516661048. Epub 2016 Aug 5.

PMID:
27481206
40.

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO.

Soelberg Sorensen P.

Mult Scler. 2016 Sep;22(10):1260-3. doi: 10.1177/1352458516644341. Epub 2016 Jul 21. Review. No abstract available.

PMID:
27444559
41.

Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.

Soelberg Sorensen P, Sellebjerg F.

Mult Scler. 2016 Aug;22(9):1112-3. doi: 10.1177/1352458516658560. Epub 2016 Jun 30. No abstract available.

PMID:
27364323
42.

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X.

Mult Scler. 2016 Oct;22(11):1386-1396. Epub 2016 May 19. Review.

PMID:
27207462
43.

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P.

Mult Scler. 2017 Feb;23(2):234-241. doi: 10.1177/1352458516643393. Epub 2016 Jul 11.

PMID:
27055806
44.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr.

45.

Ozanimod: a better or just another S1P receptor modulator?

Sørensen PS.

Lancet Neurol. 2016 Apr;15(4):345-7. doi: 10.1016/S1474-4422(16)00041-7. Epub 2016 Feb 12. No abstract available. Erratum in: Lancet Neurol. 2016 Jun;15(7):656.

PMID:
26879277
46.

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.

Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K; RECYCLINE Study Investigators.

Eur J Neurol. 2016 May;23(5):861-70. doi: 10.1111/ene.12953. Epub 2016 Feb 5.

PMID:
26848561
47.

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Sorensen PS, Blinkenberg M.

Ther Adv Neurol Disord. 2016 Jan;9(1):44-52. doi: 10.1177/1756285615601933. Review.

48.

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.

Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium.

J Immunol Methods. 2016 Mar;430:1-9. doi: 10.1016/j.jim.2016.01.004. Epub 2016 Jan 11.

PMID:
26779831
49.

Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.

Dogonowski AM, Blinkenberg M, Paulson OB, Sellebjerg F, Sørensen PS, Siebner HR, Madsen KH.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):912-4. doi: 10.1136/jnnp-2015-311375. Epub 2015 Dec 14. No abstract available.

50.

Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?

Sørensen PS.

Nat Rev Neurol. 2016 Jan;12(1):5-6. doi: 10.1038/nrneurol.2015.224. Epub 2015 Dec 4.

PMID:
26635211
51.

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.

Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P.

Mult Scler. 2016 Jun;22(7):944-54. doi: 10.1177/1352458515606809. Epub 2015 Oct 7.

PMID:
26447066
52.

Association between age at onset of multiple sclerosis and vitamin D level-related factors.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Neurology. 2016 Jan 5;86(1):88-93. doi: 10.1212/WNL.0000000000002075. Epub 2015 Oct 7.

PMID:
26446064
53.

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler. 2016 Jun;22(7):926-34. doi: 10.1177/1352458515605908. Epub 2015 Oct 2.

PMID:
26432857
54.

Physical and social environment and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler Relat Disord. 2014 Sep;3(5):600-6. doi: 10.1016/j.msard.2014.07.002. Epub 2014 Jul 21.

PMID:
26265272
55.

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G.

Nat Genet. 2015 Jul;47(7):717-726. doi: 10.1038/ng.3304. Epub 2015 May 18.

56.

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

Börnsen L, Romme Christensen J, Ratzer R, Hedegaard C, Søndergaard HB, Krakauer M, Hesse D, Nielsen CH, Sorensen PS, Sellebjerg F.

PLoS One. 2015 Mar 4;10(3):e0118830. doi: 10.1371/journal.pone.0118830. eCollection 2015.

57.

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS.

Mult Scler. 2015 Nov;21(13):1723-9. doi: 10.1177/1352458514568173. Epub 2015 Feb 19.

PMID:
25698173
58.

Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.

Olsson A, Oturai DB, Sørensen PS, Oturai PS, Oturai AB.

Mult Scler. 2015 Oct;21(12):1557-65. doi: 10.1177/1352458514566417. Epub 2015 Jan 26.

PMID:
25623251
59.

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N.

Mult Scler. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26. Review.

60.

The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review.

Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N.

Mult Scler. 2015 Mar;21(3):305-17. doi: 10.1177/1352458514564487. Epub 2015 Jan 12. Review.

61.

Therapeutic interference with leukocyte recirculation in multiple sclerosis.

Sellebjerg F, Sørensen PS.

Eur J Neurol. 2015 Mar;22(3):434-42. doi: 10.1111/ene.12668. Epub 2015 Jan 13. Review.

PMID:
25582213
62.

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.

Marrie RA, Reider N, Stuve O, Trojano M, Sorensen PS, Cutter GR, Reingold SC, Cohen J.

Mult Scler. 2015 Mar;21(3):332-41. doi: 10.1177/1352458514564488. Epub 2014 Dec 23. Review.

63.

A systematic review of the incidence and prevalence of cancer in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold SC, Cutter G.

Mult Scler. 2015 Mar;21(3):294-304. doi: 10.1177/1352458514564489. Epub 2014 Dec 22. Review.

64.

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Trojano M, Sorensen PS, Cutter G, Reingold S, Stuve O.

Mult Scler. 2015 Mar;21(3):342-9. doi: 10.1177/1352458514564486. Epub 2014 Dec 22. Review.

65.

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS.

Mult Scler. 2015 Mar;21(3):318-31. doi: 10.1177/1352458514564485. Epub 2014 Dec 22. Review.

66.

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M.

Mult Scler. 2015 Mar;21(3):282-93. doi: 10.1177/1352458514564490. Epub 2014 Dec 22. Review.

67.

Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis.

Laursen JH, Søndergaard HB, Albrechtsen A, Frikke-Schmidt R, Koch-Henriksen N, Soelberg Sørensen P, Sellebjerg F, Oturai A.

Mult Scler. 2015 Oct;21(11):1414-22. doi: 10.1177/1352458514563590. Epub 2014 Dec 22.

PMID:
25533295
68.

[Fampridine and multiple sclerosis].

Mathiesen HK, Sørensen PS.

Ugeskr Laeger. 2014 Jan 13;176(3A):V06130416. Review. Danish.

PMID:
25347174
69.

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Romme Christensen J, Romme Nielsen B, Sørensen PS, Börnsen L, Sellebjerg F.

J Neuroimmunol. 2014 Nov 15;276(1-2):195-201. doi: 10.1016/j.jneuroim.2014.08.623. Epub 2014 Aug 30.

PMID:
25218212
70.

Gender effects on treatment response to interferon-beta in multiple sclerosis.

Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

Acta Neurol Scand. 2014 Dec;130(6):374-9. doi: 10.1111/ane.12277. Epub 2014 Sep 10.

PMID:
25208455
71.

Prediction of response to interferon therapy in multiple sclerosis.

Sellebjerg F, Søndergaard HB, Koch-Henriksen N, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2014 Oct;130(4):268-75. doi: 10.1111/ane.12269. Epub 2014 Jun 18.

PMID:
24943672
72.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

73.

New management algorithms in multiple sclerosis.

Sorensen PS.

Curr Opin Neurol. 2014 Jun;27(3):246-59. doi: 10.1097/WCO.0000000000000096. Review.

PMID:
24759080
74.

Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.

Lyksborg M, Siebner HR, Sørensen PS, Blinkenberg M, Parker GJ, Dogonowski AM, Garde E, Larsen R, Dyrby TB.

PLoS One. 2014 Apr 18;9(4):e95540. doi: 10.1371/journal.pone.0095540. eCollection 2014.

75.

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F.

J Neurol. 2014 Jun;261(6):1170-7. doi: 10.1007/s00415-014-7325-8. Epub 2014 Apr 12.

PMID:
24728334
76.

Effects of fingolimod in relapsing-remitting multiple sclerosis.

Sorensen PS.

Lancet Neurol. 2014 Jun;13(6):526-7. doi: 10.1016/S1474-4422(14)70067-5. Epub 2014 Mar 28. No abstract available.

PMID:
24685277
77.

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.

Romme Christensen J, Ratzer R, Börnsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F.

Neurology. 2014 Apr 29;82(17):1499-507. doi: 10.1212/WNL.0000000000000361. Epub 2014 Mar 28.

PMID:
24682973
78.

Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis.

Wu X, Hanson LG, Skimminge A, Sorensen PS, Paulson OB, Mathiesen HK, Blinkenberg M.

Neurol Res. 2014 Aug;36(8):701-8. doi: 10.1179/1743132813Y.0000000312. Epub 2014 Jan 21.

PMID:
24620975
79.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group.

J Neurol. 2014 Apr;261(4):773-83. doi: 10.1007/s00415-014-7264-4. Epub 2014 Feb 18.

PMID:
24535134
80.

FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS.

Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, Hasan M, Wu X, Montalban X, Dziegiel MH, Sellebjerg F, Sørensen PS, Helin K, Issazadeh-Navikas S.

Nat Med. 2014 Mar;20(3):272-82. doi: 10.1038/nm.3485. Epub 2014 Feb 16.

PMID:
24531377
81.

Gender and autoimmune comorbidity in multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler. 2014 Aug;20(9):1244-51. doi: 10.1177/1352458514521515. Epub 2014 Feb 5.

PMID:
24500604
82.

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.

Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, Drulovic J, Filippi M.

Neurology. 2014 Feb 18;82(7):573-81. doi: 10.1212/WNL.0000000000000125. Epub 2014 Jan 22.

PMID:
24453078
83.

A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility.

Damotte V, Guillot-Noel L, Patsopoulos NA, Madireddy L, El Behi M; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, De Jager PL, Baranzini SE, Cournu-Rebeix I, Fontaine B.

Genes Immun. 2014 Mar;15(2):126-32. doi: 10.1038/gene.2013.70. Epub 2014 Jan 16.

84.

Multiple sclerosis impairs regional functional connectivity in the cerebellum.

Dogonowski AM, Andersen KW, Madsen KH, Sørensen PS, Paulson OB, Blinkenberg M, Siebner HR.

Neuroimage Clin. 2013 Nov 27;4:130-8. doi: 10.1016/j.nicl.2013.11.005. eCollection 2014.

85.

Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.

Mathiesen HK, Sorensen PS.

Expert Rev Neurother. 2013 Dec;13(12):1309-17. doi: 10.1586/14737175.2013.859523. Review.

PMID:
24236901
86.

Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.

Ratzer R, Søndergaard HB, Christensen JR, Börnsen L, Borup R, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Dec;19(14):1841-8. doi: 10.1177/1352458513500553. Epub 2013 Oct 1.

PMID:
24085340
87.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

88.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.

Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5.

PMID:
24009164
89.

Differential microRNA expression in blood in multiple sclerosis.

Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Dec;19(14):1849-57. doi: 10.1177/1352458513490542. Epub 2013 Jun 17.

PMID:
23773985
90.

Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls.

International Multiple Sclerosis Genetics Consortium.

Am J Hum Genet. 2013 Jun 6;92(6):854-65. doi: 10.1016/j.ajhg.2013.04.019. Epub 2013 May 23.

91.

A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis.

Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, Vittori D, Fornasiero A, Buscarinu MC; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium,2, Romano S, Salvetti M, Ristori G.

PLoS One. 2013 May 16;8(5):e63300. doi: 10.1371/journal.pone.0063300. Print 2013.

92.

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.

Møller M, Søndergaard HB, Koch-Henriksen N, Sorensen PS, Sellebjerg F, Oturai AB.

Acta Neurol Scand. 2014 Jan;129(1):27-31. doi: 10.1111/ane.12145. Epub 2013 May 14.

PMID:
23668375
93.

[Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis].

Schreiber K, Voldsgaard A, Sørensen PS.

Ugeskr Laeger. 2013 May 6;175(19):1342-4. Danish.

PMID:
23663372
94.

Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study).

Magyari M, Bach Søndergaard H, Sellebjerg F, Soelberg Sørensen P.

Mult Scler Relat Disord. 2013 Apr;2(2):141-6. doi: 10.1016/j.msard.2012.10.001. Epub 2012 Dec 11.

PMID:
25877635
95.

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.

Mult Scler. 2013 Aug;19(9):1226-9. doi: 10.1177/1352458513481010. Epub 2013 Mar 18.

PMID:
23508652
96.

Reproduction and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler. 2013 Oct;19(12):1604-9. doi: 10.1177/1352458513481397. Epub 2013 Mar 18.

PMID:
23508651
97.

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Romme Christensen J, Börnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, Sørensen PS, Sellebjerg F.

PLoS One. 2013;8(3):e57820. doi: 10.1371/journal.pone.0057820. Epub 2013 Mar 1. Erratum in: PLoS One. 2013 Mar 5;8(3):.

98.

Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis.

Dogonowski AM, Siebner HR, Soelberg Sørensen P, Paulson OB, Dyrby TB, Blinkenberg M, Madsen KH.

Acta Neurol Scand. 2013 Nov;128(5):328-35. doi: 10.1111/ane.12121. Epub 2013 Mar 6.

PMID:
23461607
99.

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.

Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, Jensen PE, Moiola L, Myhr KM, Oturai A, Schippling S, Siva A, Sorensen PS, Trampe AK, Weber T, Potts J, Plavina T, Paes D, Subramanyam M, Wiendl H, Dib H, Uren D, Hemmer B, Buck D.

Mult Scler. 2013 Oct;19(11):1533-8. doi: 10.1177/1352458513477925. Epub 2013 Mar 4.

PMID:
23459571
100.

Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression.

Romme Christensen J, Börnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, Sørensen PS, Sellebjerg F.

PLoS One. 2013 Mar 5;8(3). doi: 10.1371/annotation/b4e623eb-4950-48d9-8d85-8d70426d95a3. eCollection 2013.

101.

Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS.

Pugliatti M, Eskic D, Mikolcić T, Pitschnau-Michel D, Myhr KM, Sastre-Garriga J, Otero S, Wieczynska L, Torje C, Holloway E, Rienhoff O, Friede T, Buckow K, Ellenberger D, Hillert J, Glaser A, Flachenecker P, Fuge J, Schyns-Liharska T, Kasilingam E, Moretti A, Thalheim C; EUReMS Consortium.

Acta Neurol Scand Suppl. 2012;(195):24-30. doi: 10.1111/ane.12024.

PMID:
23278653
102.

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ.

J Neurol. 2013 Apr;260(4):1136-46. doi: 10.1007/s00415-012-6775-0. Epub 2012 Dec 21.

PMID:
23263473
103.

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

Börnsen L, Christensen JR, Ratzer R, Oturai AB, Sørensen PS, Søndergaard HB, Sellebjerg F.

PLoS One. 2012;7(11):e47578. doi: 10.1371/journal.pone.0047578. Epub 2012 Nov 30.

104.

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.

Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Jun;19(7):877-84. doi: 10.1177/1352458512466929. Epub 2012 Nov 24.

PMID:
23178691
105.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
106.

[Multiple Sclerosis Treatment Registry].

Thirup P, Koch-Henriksen N, Sørensen PS.

Ugeskr Laeger. 2012 Oct 15;174(42):2537. Danish. No abstract available.

PMID:
23079440
107.

Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans.

Brambilla P, Esposito F, Lindstrom E, Sorosina M, Giacalone G, Clarelli F, Rodegher M, Colombo B, Moiola L, Ghezzi A, Capra R, Collimedaglia L, Coniglio G, Celius EG, Galimberti D, Sørensen PS, Martinelli V, Oturai AB, Harbo HF, Hillert J, Comi G, Martinelli-Boneschi F.

Neurosci Lett. 2012 Nov 21;530(2):155-60. doi: 10.1016/j.neulet.2012.10.008. Epub 2012 Oct 13.

PMID:
23069673
108.

FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.

Sellebjerg F, Krakauer M, Khademi M, Olsson T, Sørensen PS.

Clin Exp Immunol. 2012 Nov;170(2):149-55. doi: 10.1111/j.1365-2249.2012.04654.x.

109.

[Deaths related to physical restraint of very agitated persons should be possible to avoid].

Sørensen PS.

Ugeskr Laeger. 2012 Oct 1;174(40):2367. Danish. No abstract available.

PMID:
23031295
110.

Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis.

Dogonowski AM, Siebner HR, Sørensen PS, Wu X, Biswal B, Paulson OB, Dyrby TB, Skimminge A, Blinkenberg M, Madsen KH.

Mult Scler. 2013 Apr;19(5):559-66. doi: 10.1177/1352458512460416. Epub 2012 Sep 25.

PMID:
23012251
111.

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.

Romme Christensen J, Börnsen L, Hesse D, Krakauer M, Sørensen PS, Søndergaard HB, Sellebjerg F.

J Neuroinflammation. 2012 Sep 14;9:215. doi: 10.1186/1742-2094-9-215.

112.

Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).

Sørensen PS.

Mult Scler. 2012 Aug;18(8):1070-2. doi: 10.1177/1352458512451946. No abstract available.

PMID:
22807471
113.

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Sellebjerg F, Krakauer M, Limborg S, Hesse D, Lund H, Langkilde A, Søndergaard HB, Sørensen PS.

PLoS One. 2012;7(6):e35927. doi: 10.1371/journal.pone.0035927. Epub 2012 Jun 6.

114.

Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.

Sellebjerg F, Hesse D, Limborg S, Lund H, Søndergaard HB, Krakauer M, Sørensen PS.

Mult Scler. 2013 Feb;19(2):179-87. doi: 10.1177/1352458512450353. Epub 2012 May 31.

PMID:
22653658
115.

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.

Jensen PE, Sellebjerg F, Søndergaard HB, Sørensen PS.

Eur J Neurol. 2012 Oct;19(10):1311-7. doi: 10.1111/j.1468-1331.2012.03721.x. Epub 2012 May 5.

PMID:
22564111
116.

Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis.

Blinkenberg M, Akeson P, Sillesen H, Lövgaard S, Sellebjerg F, Paulson OB, Siebner HR, Sørensen PS.

Acta Neurol Scand. 2012 Dec;126(6):421-7. doi: 10.1111/j.1600-0404.2012.01671.x. Epub 2012 Apr 25.

PMID:
22530753
117.

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.

Cohen JA, Reingold SC, Polman CH, Wolinsky JS; International Advisory Committee on Clinical Trials in Multiple Sclerosis.

Lancet Neurol. 2012 May;11(5):467-76. doi: 10.1016/S1474-4422(12)70059-5. Review.

PMID:
22516081
118.

[Diagnosis of multiple sclerosis--the 2010 revision of the McDonald criteria].

Mathiesen HK, Sørensen PS.

Ugeskr Laeger. 2012 Mar 26;174(13):862-5. Danish.

PMID:
22456173
119.

Prediction of antibody persistency from antibody titres to natalizumab.

Jensen PE, Koch-Henriksen N, Sellebjerg F, Sørensen PS.

Mult Scler. 2012 Oct;18(10):1493-9. Epub 2012 Mar 27.

PMID:
22454098
120.

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.

Mult Scler. 2012 Feb;18(2):143-52. doi: 10.1177/1352458511435105. Review.

PMID:
22312009
121.

Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox.

Sørensen PS.

Mult Scler. 2012 Feb;18(2):131-2. doi: 10.1177/1352458511419438. No abstract available.

PMID:
22312007
122.

Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012.

Bendtsen L, Birk S, Kasch H, Aegidius K, Sørensen PS, Thomsen LL, Poulsen L, Rasmussen MJ, Kruuse C, Jensen R; Danish Headache Society.

J Headache Pain. 2012 Feb;13 Suppl 1:S1-29. doi: 10.1007/s10194-011-0402-9.

123.

Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.

Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A.

Clin Drug Investig. 2012 Jan;32(1):15-27.

PMID:
27933596
124.

Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.

Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sørensen P, Vermersch P, Hamlett A, Kurukulasuriya N; CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.

Mult Scler Relat Disord. 2012 Jan;1(1):49-54. doi: 10.1016/j.msard.2011.08.006. Epub 2011 Sep 15.

PMID:
25876451
125.
126.

Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study.

Blinkenberg M, Mathiesen HK, Tscherning T, Jønsson A, Svarer C, Holm S, Sellebjerg F, Paulson OB, Hanson LG, Sorensen PS.

Neurol Res. 2012 Jan;34(1):52-8. doi: 10.1179/1743132811Y.0000000059.

PMID:
22196862
127.

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.

Sellebjerg F, Hedegaard CJ, Krakauer M, Hesse D, Lund H, Nielsen CH, Søndergaard HB, Sørensen PS.

Mult Scler. 2012 Mar;18(3):305-13. doi: 10.1177/1352458511420268. Epub 2011 Oct 21.

PMID:
22020419
128.

Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.

Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A; CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.

Clin Drug Investig. 2012 Jan 1;32(1):15-27. doi: 10.2165/11593310-000000000-00000.

PMID:
22017519
129.

Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?

Koch-Henriksen N, Sorensen PS.

J Neurol Sci. 2011 Dec 15;311(1-2):58-63. doi: 10.1016/j.jns.2011.09.003. Epub 2011 Oct 7. Review.

PMID:
21982346
130.

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators.

Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5.

PMID:
21975206
131.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

132.

Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue.

Lund H, Jønsson A, Andresen J, Rostrup E, Paulson OB, Sørensen PS.

Acta Neurol Scand. 2012 May;125(5):338-44. doi: 10.1111/j.1600-0404.2011.01574.x. Epub 2011 Jul 27.

PMID:
21793807
133.

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J.

Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1. Review.

PMID:
21777829
134.

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators.

Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2.

PMID:
21742556
135.

Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655.

Søndergaard HB, Sellebjerg F, Hillert J, Olsson T, Kockum I, Lindén M, Mero IL, Myhr KM, Celius EG, Harbo HF, Christensen JR, Börnsen L, Sørensen PS, Oturai AB.

Eur J Hum Genet. 2011 Oct;19(10):1100-3. doi: 10.1038/ejhg.2011.88. Epub 2011 May 25.

136.

The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study.

International Multiple Sclerosis Genetics Consortium.

PLoS One. 2011 Apr 28;6(4):e18813. doi: 10.1371/journal.pone.0018813.

137.

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R.

Mult Scler. 2011 Sep;17(9):1074-8. doi: 10.1177/1352458511404271. Epub 2011 Apr 20.

PMID:
21511692
138.

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.

Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S; CLARITY study group.

Lancet Neurol. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0.

PMID:
21397565
139.

Principles of a new treatment algorithm in multiple sclerosis.

Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T.

Expert Rev Neurother. 2011 Mar;11(3):351-62. doi: 10.1586/ern.11.15. Review.

PMID:
21375441
140.

Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab.

Sørensen PS, Koch-Henriksen N, Jensen PE.

Neurology. 2011 Feb 22;76(8):759-60. doi: 10.1212/WNL.0b013e31820d62a4. No abstract available.

PMID:
21339504
141.

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.

Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ; CLARITY Study Group.

Mult Scler. 2011 May;17(5):578-93. doi: 10.1177/1352458510391344. Epub 2011 Jan 12.

PMID:
21228029
142.

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.

Börnsen L, Khademi M, Olsson T, Sørensen PS, Sellebjerg F.

Mult Scler. 2011 Jan;17(1):32-42. doi: 10.1177/1352458510382247. Epub 2010 Oct 4.

PMID:
20921238
143.

Demyelination versus remyelination in progressive multiple sclerosis.

Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, Laursen H.

Brain. 2010 Oct;133(10):2983-98. doi: 10.1093/brain/awq250. Epub 2010 Sep 20.

PMID:
20855416
144.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.

Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.

PMID:
20610349
145.

Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.

Enevold C, Oturai AB, Sørensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K.

Mult Scler. 2010 Aug;16(8):942-9. doi: 10.1177/1352458510373264. Epub 2010 Jul 1.

PMID:
20595247
146.

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

Hesse D, Krakauer M, Lund H, Søndergaard HB, Limborg SJ, Sørensen PS, Sellebjerg F.

Eur J Neurol. 2011 Feb;18(2):266-72. doi: 10.1111/j.1468-1331.2010.03116.x.

PMID:
20561040
147.

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.

International Multiple Sclerosis Genetics Conssortium (IMSGC).

Genes Immun. 2010 Jul;11(5):397-405. doi: 10.1038/gene.2010.28. Epub 2010 Jun 17.

148.

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.

Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.

Lancet Neurol. 2010 Jul;9(7):672-80. doi: 10.1016/S1474-4422(10)70132-0. Epub 2010 Jun 9. Erratum in: Lancet Neurol. 2010 Aug;9(8):759.

PMID:
20542736
149.

EFNS guidelines on diagnosis and management of neuromyelitis optica.

Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B.

Eur J Neurol. 2010 Aug;17(8):1019-32. doi: 10.1111/j.1468-1331.2010.03066.x. Epub 2010 Jun 7. Review.

PMID:
20528913
150.

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.

Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F.

Neurology. 2010 May 4;74(18):1455-62. doi: 10.1212/WNL.0b013e3181dc1a94.

PMID:
20439848
151.

The changing demographic pattern of multiple sclerosis epidemiology.

Koch-Henriksen N, Sørensen PS.

Lancet Neurol. 2010 May;9(5):520-32. doi: 10.1016/S1474-4422(10)70064-8. Review.

PMID:
20398859
152.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
153.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group.

N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.

154.

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group.

Mult Scler. 2010 Feb;16(2):197-207. doi: 10.1177/1352458509357065. Epub 2009 Dec 22.

PMID:
20028707
155.

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

Sellebjerg F, Börnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, Sørensen PS.

Neurology. 2009 Dec 8;73(23):2003-10. doi: 10.1212/WNL.0b013e3181c5b457.

PMID:
19996075
156.

Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis.

Ockinger J, Stridh P, Beyeen AD, Lundmark F, Seddighzadeh M, Oturai A, Sørensen PS, Lorentzen AR, Celius EG, Leppä V, Koivisto K, Tienari PJ, Alfredsson L, Padyukov L, Hillert J, Kockum I, Jagodic M, Olsson T.

Genes Immun. 2010 Mar;11(2):142-54. doi: 10.1038/gene.2009.82. Epub 2009 Oct 29.

PMID:
19865101
157.

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.

Engel WK.

Neurology. 2009 Sep 29;73(13):1077; author reply 1077-8. doi: 10.1212/WNL.0b013e3181ab6b81. No abstract available.

PMID:
19786702
158.

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.

Hesse D, Sellebjerg F, Sorensen PS.

Neurology. 2009 Aug 4;73(5):372-7. doi: 10.1212/WNL.0b013e3181b04c98.

PMID:
19652141
159.

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, Koch-Henriksen N, Svejgaard A, Soelberg Sørensen P.

Eur J Neurol. 2009 Dec;16(12):1291-8. doi: 10.1111/j.1468-1331.2009.02716.x. Epub 2009 Jun 22.

PMID:
19558503
160.

Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1.

Enevold C, Oturai AB, Sørensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K.

J Neuroimmunol. 2009 Jul 25;212(1-2):125-31. doi: 10.1016/j.jneuroim.2009.04.008. Epub 2009 May 17.

PMID:
19450885
161.

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.

Lancet Neurol. 2009 Jun;8(6):519-29. doi: 10.1016/S1474-4422(09)70085-7. Epub 2009 May 4.

PMID:
19409854
162.

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS.

Eur J Neurol. 2009 Mar;16(3):420-3. doi: 10.1111/j.1468-1331.2008.02517.x.

PMID:
19364368
163.

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

Sorensen PS.

Eur J Neurol. 2009 Mar;16(3):287-8. doi: 10.1111/j.1468-1331.2008.02518.x. No abstract available.

PMID:
19364360
164.

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H.

Brain. 2009 May;132(Pt 5):1175-89. doi: 10.1093/brain/awp070. Epub 2009 Mar 31.

165.

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.

Mult Scler. 2009 May;15(5):601-5. doi: 10.1177/1352458508101946. Epub 2009 Mar 19.

PMID:
19299439
166.

Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP.

Hedegaard CJ, Chen N, Sellebjerg F, Sørensen PS, Leslie RG, Bendtzen K, Nielsen CH.

Immunology. 2009 Sep;128(1 Suppl):e451-61. doi: 10.1111/j.1365-2567.2008.02999.x. Epub 2008 Dec 18.

167.

Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis.

Nielsen TR, Rostgaard K, Askling J, Steffensen R, Oturai A, Jersild C, Koch-Henriksen N, Sørensen PS, Hjalgrim H.

Mult Scler. 2009 Apr;15(4):431-6. doi: 10.1177/1352458508100037. Epub 2009 Jan 19.

PMID:
19153174
168.

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.

O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group.

Neurology. 2009 Jan 6;72(1):73-9. doi: 10.1212/01.wnl.0000338569.32367.3d.

PMID:
19122034
169.

Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.

Hesse D, Frederiksen JL, Koch-Henriksen N, Schreiber K, Stenager E, Heltberg A, Ravnborg M, Bendtzen K, Sellebjerg F, Sorensen PS.

Eur J Neurol. 2009 Jan;16(1):43-7. doi: 10.1111/j.1468-1331.2008.02336.x.

PMID:
19087149
170.

Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away?

Sorensen PS.

Eur J Neurol. 2009 Jan;16(1):1-2. doi: 10.1111/j.1468-1331.2008.02265.x. No abstract available.

PMID:
19087140
171.

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.

Ravnborg M, Bendtzen K, Christensen O, Jensen PE, Hesse D, Tovey MG, Sørensen PS.

Mult Scler. 2009 Mar;15(3):323-8. doi: 10.1177/1352458508099476. Epub 2008 Nov 21.

PMID:
19028832
172.

Can we spot the IFNbeta nonresponders?

Sorensen PS.

Neurology. 2008 Dec 9;71(24):1936-7. doi: 10.1212/01.wnl.0000333667.54693.1e. Epub 2008 Oct 29. No abstract available.

PMID:
18971447
173.

Oral fumarate for relapsing-remitting multiple sclerosis.

Sorensen PS, Sellebjerg F.

Lancet. 2008 Oct 25;372(9648):1447-8. doi: 10.1016/S0140-6736(08)61605-0. No abstract available.

PMID:
18970966
174.

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B; EFNS.

Eur J Neurol. 2008 Sep;15(9):893-908. doi: 10.1111/j.1468-1331.2008.02246.x. Erratum in: Eur J Neurol. 2009 Apr;16(4):547.

PMID:
18796075
175.

REGARD: what can we learn from randomised, open-label, head-to-head studies?

Sørensen PS.

Lancet Neurol. 2008 Oct;7(10):864-6. doi: 10.1016/S1474-4422(08)70201-1. Epub 2008 Sep 11. No abstract available.

PMID:
18789767
176.

[Magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis].

Mathiesen HK, Ravnborg M, Sørensen PS.

Ugeskr Laeger. 2008 Aug 18;170(34):2579-81. Danish.

PMID:
18761844
177.

Neutralizing antibodies against interferon-Beta.

Sorensen PS.

Ther Adv Neurol Disord. 2008 Sep;1(2):125-41. doi: 10.1177/1756285608095144.

178.

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group.

Mult Scler. 2009 Feb;15(2):219-28. doi: 10.1177/1352458508097299. Epub 2008 Aug 28.

PMID:
18755819
179.

The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.

Hedegaard CJ, Krakauer M, Bendtzen K, Sørensen PS, Sellebjerg F, Nielsen CH.

Clin Immunol. 2008 Oct;129(1):80-9. doi: 10.1016/j.clim.2008.06.007. Epub 2008 Jul 23.

PMID:
18653385
180.

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.

Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group.

Neurology. 2008 Jul 22;71(4):265-71. doi: 10.1212/01.wnl.0000318281.98220.6f.

PMID:
18645164
181.

Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis.

Bramow S, Faber-Rod JC, Jacobsen C, Kutzelnigg A, Patrikios P, Sorensen PS, Lassmann H, Laursen H.

Mult Scler. 2008 Jun;14(5):711-5. doi: 10.1177/1352458507087848.

PMID:
18566036
182.

[Biological treatment of multiple sclerosis].

Sørensen PS, Sellebjerg F.

Ugeskr Laeger. 2008 Jun 9;170(24):2156-9. Danish.

PMID:
18565303
183.

The SH2D2A gene and susceptibility to multiple sclerosis.

Lorentzen AR, Smestad C, Lie BA, Oturai AB, Akesson E, Saarela J, Myhr KM, Vartdal F, Celius EG, Sørensen PS, Hillert J, Spurkland A, Harbo HF.

J Neuroimmunol. 2008 Jul 15;197(2):152-8. doi: 10.1016/j.jneuroim.2008.04.037. Epub 2008 Jun 12.

PMID:
18554728
184.

Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?

Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.

Mult Scler. 2008 Jul;14(6):837-42. doi: 10.1177/1352458508088942. Epub 2008 May 27.

PMID:
18505772
185.

Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.

Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F.

Mult Scler. 2008 Jun;14(5):622-30. doi: 10.1177/1352458507087136. Epub 2008 Apr 18.

PMID:
18424480
186.

Gene expression analysis of interferon-beta treatment in multiple sclerosis.

Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, Oturai A, Svejgaard A, Soelberg Sørensen P, Ryder LP.

Mult Scler. 2008 Jun;14(5):615-21. doi: 10.1177/1352458507085976. Epub 2008 Apr 11.

PMID:
18408020
187.

[Multiple sclerosis--the significance of genes. The Danish Society of Neurology].

Sellebjerg F, Oturai A, Sørensen PS; Dansk Neurologisk Selskab.

Ugeskr Laeger. 2008 Mar 17;170(12):1046. Danish. No abstract available.

PMID:
18397664
188.

Editorial.

Hillert J, Soelberg Sørensen P.

J Neurol. 2008 Mar;255 Suppl 1:1-2. doi: 10.1007/s00415-008-1001-9. No abstract available.

PMID:
18317670
189.

Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.

Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS; European NABINMS Consortium.

J Int Med Res. 2008 Jan-Feb;36(1):204-8; author reply 208-10. No abstract available.

PMID:
18230281
190.

Intravenous polyclonal human immunoglobulins in multiple sclerosis.

Soelberg Sorensen P.

Neurodegener Dis. 2008;5(1):8-15. Review.

PMID:
18075269
191.

[Diagnosis of multiple sclerosis: revision of the McDonald criteria].

Mathiesen HK, Ravnborg MH, Sørensen PS.

Ugeskr Laeger. 2007 Nov 5;169(45):3853-6. Danish.

PMID:
18031657
193.

Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.

Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; RNF Study Group.

Clin Ther. 2007 Jun;29(6):1128-45.

PMID:
17692727
194.

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy.

Hesse D, Sørensen PS.

Eur J Neurol. 2007 Aug;14(8):850-9. Review.

PMID:
17662004
195.

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?

Sorensen PS, Koch-Henriksen N, Bendtzen K.

Mult Scler. 2007 Jun;13(5):616-21. Epub 2007 Feb 9.

PMID:
17548440
196.

A follow-up study of Nordic multiple sclerosis candidate gene regions.

Datta P, Harbo HF, Ryder LP, Akesson E, Benedikz J, Celius EG, Andersen O, Myhr KM, Sandberg-Wollheim M, Hillert J, Svejgaard A, Sorensen PS, Spurkland A, Oturai A.

Mult Scler. 2007 Jun;13(5):584-9. Epub 2007 Feb 9.

PMID:
17548436
197.

Resource allocation to brain research in Europe.

Sørensen PS.

Eur J Neurol. 2007 Jun;14(6):597. No abstract available.

PMID:
17539933
198.

Widespread demyelination in the cerebellar cortex in multiple sclerosis.

Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H.

Brain Pathol. 2007 Jan;17(1):38-44.

PMID:
17493036
199.

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS.

J Neurol. 2007 Jul;254(7):827-37. Epub 2007 Apr 24. Review.

PMID:
17457510
200.

Health-related quality of life in secondary progressive multiple sclerosis.

Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Sandberg-Wollheim M, Sorensen PS, Myhr KM; Nordic SPMS study group.

Mult Scler. 2007 Apr;13(3):386-92.

PMID:
17439908

Supplemental Content

Loading ...
Support Center